Evaluation of the Vasoconstriction Properties of MC2-01 Cream

• Status: Completed
• Trial end date: 2018-11-23

Summary

The objective of this trial is to compare the vasoconstriction potential

• Phase: Phase 1

Details

• Lead Sponsor: Drug Delivery Solutions Ltd. (part of MC2 Therapeutics); MC2 Therapeutics
• Treatments: Betamethasone; Betamethasone benzoate; Betamethasone sodium phosphate; Betamethasone Valerate; Betamethasone-17,21-dipropionate; Clobetasol; Cortisol succinate; Desonide; Emollients; Hydrocortisone; Hydrocortisone 17-butyrate 21-propionate; Hydrocortisone acetate; Hydrocortisone-17-butyrate; Triamcinolone; Triamcinolone Acetonide; Triamcinolone diacetate; Triamcinolone hexacetonide